- Published on
Clinical Toxicology — Teratogens and Prenatal Toxic Exposures
1. Overview
Teratology is the study of abnormal development and the causes of congenital abnormalities.
A teratogen is an environmental, chemical, biological, physical, or pharmacologic exposure capable of disrupting embryonic or fetal development.
Contemporary prenatal toxicology encompasses more than structural malformations. Adverse outcomes may include:
- Congenital structural abnormalities.
- Pregnancy loss and stillbirth.
- Fetal growth restriction.
- Impaired organ function.
- Neurodevelopmental abnormalities.
- Neonatal toxicity or withdrawal.
- Long-term reproductive or health effects.
An exposure that causes fetal growth restriction or impaired brain development may be clinically important even without a visible birth defect.
An exposure to a known teratogen does not mean that fetal injury is inevitable.
Risk assessment must consider the specific agent, absorbed dose, duration, gestational age, maternal health, and quality of the available evidence.
The principal management goals are to identify and stop avoidable harmful exposures, treat maternal illness effectively, provide individualized risk counseling, and arrange appropriate prenatal evaluation.
2. Baseline risk of congenital abnormalities
Congenital abnormalities can arise from genetic, chromosomal, environmental, or multifactorial causes.
Many occur without an identifiable environmental exposure.
The CDC estimates that approximately 1 in 33 babies, or about 3%, is born with a birth defect in the United States each year.
This background risk must be considered when interpreting reports of abnormalities following medication exposure.
Risk interpretation
A birth defect occurring after exposure does not prove that the exposure caused it.
Similarly, a medication associated with increased relative risk may still have a low absolute risk.
For example, doubling a risk from 1 in 1,000 to 2 in 1,000 represents a meaningful relative increase, but the absolute increase is 1 additional case per 1,000 pregnancies.
Important principle
Teratogenic risk should be communicated using absolute risks whenever reliable data are available.
Older studies that reported isolated percentages without appropriate comparison groups may overstate or misrepresent risk.
3. Developmental timing
Gestational age is one of the most important determinants of risk.
Gestational age is conventionally measured from the first day of the last menstrual period, approximately two weeks before fertilization in a typical menstrual cycle.
Preimplantation period
The first two weeks after conception, approximately gestational weeks 3–4, are often described as the all-or-none period.
During this period, a severe exposure may result in pregnancy loss, while a less severe exposure may produce no recognizable structural abnormality.
However, this is a general principle with exceptions, not a guarantee of safety.
Organogenesis
Major organ formation occurs primarily during approximately gestational weeks 5–10, corresponding to weeks 3–8 after conception.
This is the period of greatest vulnerability to many major structural malformations.
Fetal period
After organogenesis, exposure may still disrupt:
- Brain development.
- Fetal growth.
- Kidney function.
- Bone and tooth development.
- Endocrine function.
- Hearing and vision.
- Organ maturation.
Late pregnancy
Some medications cause important fetal or neonatal toxicity without producing an anatomical malformation.
Examples include premature ductus arteriosus constriction, fetal kidney dysfunction, respiratory depression, hypoglycemia, and neonatal withdrawal.
The absence of first-trimester exposure does not establish that a drug is harmless later in pregnancy.
4. Mechanisms of teratogenicity
Potential mechanisms include:
DNA and chromosome injury: Disruption of replication, repair, or cell division.
Altered signaling pathways: Interference with cellular differentiation, pattern formation, or organ development.
Folate antagonism: Impaired nucleotide synthesis and rapid cell growth.
Endocrine disruption: Changes in androgen, estrogen, or thyroid signaling.
Vascular injury: Impaired placental circulation or fetal tissue perfusion.
Oxidative stress: Cellular injury caused by disrupted redox balance.
Nutritional deficiency: Insufficient folate, iodine, or other nutrients required for normal development.
Functional toxicity: Altered neuronal development, endocrine regulation, or organ function without a visible structural defect.
Several mechanisms may occur simultaneously.
5. Evidence assessment
Established human teratogens
These agents have convincing evidence linking exposure with specific adverse developmental outcomes.
Suspected or possible teratogens
Some agents show concerning animal findings or inconsistent human associations, but a causal relationship remains uncertain.
Agents without demonstrated teratogenicity
Absence of convincing evidence of harm does not necessarily establish complete safety.
However, a lack of evidence must not automatically be interpreted as proof of teratogenicity.
Problems with observational research
Studies may be affected by:
- Maternal illness.
- Genetic risk.
- Smoking or alcohol use.
- Other medications.
- Differences in prenatal care.
- Dose and timing uncertainty.
- Selective reporting.
The underlying condition being treated may itself increase pregnancy risks.
Clinical principle
Both the risks of treatment and the risks of untreated disease must be considered.
6. Contemporary medication labeling
The historical FDA pregnancy letter categories A, B, C, D, and X are obsolete.
They were replaced by the Pregnancy and Lactation Labeling Rule, effective June 30, 2015.
Modern prescription labeling provides narrative information on:
Pregnancy: Risk summary, clinical considerations, and supporting evidence.
Lactation: Drug transfer into milk, potential infant effects, and clinical considerations.
Females and males of reproductive potential: Pregnancy testing, contraception, and reproductive effects when relevant.
Important clinical correction
A former category B drug was not necessarily safer than every former category C drug.
Similarly, a former category D medication was not automatically inappropriate in every pregnancy.
Medication decisions must be based on drug-specific evidence and the patient’s clinical circumstances.
7. Retinoids
Isotretinoin
Oral isotretinoin is a potent established human teratogen.
Exposure during pregnancy increases the risk of miscarriage and major congenital abnormalities.
Potential findings include:
- Ear abnormalities.
- Craniofacial malformations.
- Cardiac defects.
- Central nervous system abnormalities.
- Thymic abnormalities.
- Cleft palate.
- Neurodevelopmental impairment.
MotherToBaby reports that the chance of miscarriage may be as high as approximately 40% after early pregnancy exposure, while birth defects have been reported in 35% or more of exposed infants in certain datasets.
These estimates vary by study and should not be applied mechanically to every exposure.
Pregnancy prevention
Oral isotretinoin is contraindicated during pregnancy.
The United States uses the iPLEDGE risk-management program to reduce fetal exposure.
The FDA approved modifications to iPLEDGE in February 2026, while maintaining pregnancy-prevention and monitoring requirements.
Other systemic retinoids
Acitretin and related systemic retinoids also have major reproductive risks.
Acitretin requires particularly careful preconception counseling because pregnancy avoidance must continue for three years after treatment ends.
Topical retinoids
Topical tretinoin is absorbed to a much smaller extent than oral isotretinoin.
Human studies have not established a comparable major malformation risk after appropriate topical use.
Nevertheless, topical retinoids are generally avoided during pregnancy when suitable alternatives are available.
Do not equate accidental topical tretinoin exposure with systemic isotretinoin exposure.
8. Antiseizure medications
Valproate
Valproate is among the most important established medication-related developmental toxicants.
Risks include:
- Neural tube defects.
- Other major congenital malformations.
- Reduced offspring cognitive performance.
- Increased risk of neurodevelopmental disorders, including autism spectrum disorder.
Risk is influenced by dose and exposure circumstances.
Current guidance
The 2024 guideline from the American Academy of Neurology, American Epilepsy Society, and Society for Maternal-Fetal Medicine recommends avoiding valproate during pregnancy whenever clinically feasible.
Carbamazepine
Carbamazepine is associated with an increased risk of neural tube defects and certain other abnormalities.
The risk depends on treatment circumstances and may be influenced by dose and polytherapy.
Phenytoin
Prenatal phenytoin exposure has been associated with the fetal hydantoin phenotype, including craniofacial and digital abnormalities.
However, the historical percentages for complete or partial syndromes should not be treated as universal contemporary risk estimates.
Topiramate
Topiramate exposure has been associated with an increased risk of oral clefts and small-for-gestational-age infants.
Lamotrigine, levetiracetam, and oxcarbazepine
These agents generally have more favorable pregnancy malformation profiles than valproate in contemporary pregnancy registries.
They may be preferred when appropriate for the epilepsy syndrome.
Critical treatment principle
Do not abruptly stop effective antiseizure medication after discovering pregnancy.
Generalized convulsive seizures can cause significant maternal and fetal harm.
Medication changes require neurologic and obstetric assessment.
Folic acid
The 2024 epilepsy-in-pregnancy guideline recommends at least 0.4 mg of folic acid daily before conception and throughout pregnancy for patients taking antiseizure medication.
Higher doses may be considered for selected patients according to individual risk and local guidance.
9. Anticoagulants
Warfarin
Warfarin crosses the placenta and can cause fetal injury.
Early exposure during critical developmental periods may cause fetal warfarin syndrome, characterized by abnormalities such as nasal hypoplasia and stippled epiphyses.
Other effects include fetal bleeding, intracranial injury, and pregnancy loss.
Risk variation
Risk depends on dose, timing, and the underlying indication.
The historical assertion that exactly one in six exposed pregnancies results in deformity should not be presented as universally applicable.
Mechanical heart valves
Warfarin may provide important maternal protection in patients with mechanical heart valves.
Substituting anticoagulation can increase maternal valve-thrombosis risk if not managed carefully.
These pregnancies require multidisciplinary management.
Heparins
Unfractionated heparin and low-molecular-weight heparins do not appreciably cross the placenta and are commonly used when anticoagulation is required during pregnancy.
Direct oral anticoagulants
Drugs such as apixaban and rivaroxaban are generally avoided during pregnancy because human pregnancy safety data are inadequate and other options are preferred.
10. Methotrexate and other antineoplastic medications
Methotrexate
Methotrexate interferes with folate metabolism.
It can cause pregnancy loss and a characteristic pattern of abnormalities involving the skull, face, limbs, and skeleton.
The risk is particularly important during early organogenesis.
Historical correction
Routine folic acid supplementation should not be presented as a method that reliably prevents fetal injury after methotrexate exposure.
Folic acid is important for nutritional support, but it does not guarantee protection against methotrexate teratogenicity.
Folinic acid
Folinic acid, also called leucovorin, is used for specific methotrexate toxicities.
Its role after pregnancy exposure depends on the circumstances and requires specialist assessment.
Cancer chemotherapy
Many cytotoxic agents can impair embryonic development or cause pregnancy loss.
However, the risk depends greatly on the specific drug and trimester.
The older chapter’s blanket estimate of a 10–50% malformation rate for all antineoplastic agents is not appropriate.
Some cancers can be treated during selected periods of pregnancy using specialist-designed regimens.
Cancer treatment during pregnancy requires multidisciplinary maternal–fetal medicine and oncology care.
11. Angiotensin-converting enzyme inhibitors and ARBs
Examples include:
- Enalapril.
- Lisinopril.
- Ramipril.
- Losartan.
- Valsartan.
First-trimester exposure
Modern evidence does not establish a consistent independent major-malformation risk from ACE inhibitors during the first trimester.
Underlying hypertension, diabetes, and other medical factors may explain some reported associations.
Second- and third-trimester exposure
Exposure during later pregnancy can cause serious fetal injury, including:
- Fetal kidney dysfunction.
- Oligohydramnios.
- Impaired skull ossification.
- Pulmonary hypoplasia.
- Growth restriction.
- Neonatal kidney failure.
- Fetal or neonatal death.
Management
ACE inhibitors and ARBs should generally be replaced with pregnancy-appropriate alternatives when pregnancy is recognized.
After significant later-pregnancy exposure, ultrasound assessment of amniotic fluid, fetal kidneys, growth, and other relevant findings may be indicated.
Clinical principle
The risk associated with ACE inhibitors and ARBs is particularly dependent on gestational timing.
12. Nonsteroidal anti-inflammatory drugs
An important omission from the historical chapter is late-pregnancy NSAID toxicity.
Examples include ibuprofen, naproxen, diclofenac, and celecoxib.
Around 20 weeks or later
NSAIDs may cause fetal kidney dysfunction and oligohydramnios.
Around 30 weeks or later
NSAIDs can cause premature constriction or closure of the fetal ductus arteriosus.
FDA recommendations
The FDA generally advises avoiding NSAIDs from approximately 20 weeks unless specifically directed by a clinician.
If use between 20 and 30 weeks is necessary, exposure should be minimized.
NSAIDs are generally avoided at approximately 30 weeks and beyond.
Low-dose aspirin
Prescribed low-dose aspirin for certain pregnancy-related indications is an important exception.
It should not be stopped automatically because of general NSAID warnings.
13. Lithium
Lithium is used primarily for bipolar disorder.
Cardiac malformations
Some studies suggest a modest increase in fetal cardiac malformations, including right-sided cardiac defects.
Ebstein anomaly is a recognized concern, although its absolute occurrence is much lower than suggested by some older reports.
Risk-benefit assessment
Untreated bipolar disorder can cause severe maternal illness and relapse.
Therefore, lithium is not automatically inappropriate during every pregnancy.
Monitoring
Management may involve maternal lithium concentrations, kidney function, thyroid monitoring, and targeted fetal cardiac assessment.
Neonatal effects
Late pregnancy exposure may contribute to neonatal hypotonia, feeding difficulties, or other toxicity.
Clinical principle
Lithium management should balance fetal risk against the dangers of severe maternal psychiatric relapse.
14. Thyroid medications and iodine
Methimazole
Early pregnancy methimazole exposure has been associated with a pattern of unusual malformations, including aplasia cutis, choanal atresia, and esophageal atresia.
Not all studies demonstrate increased risk, and the absolute risk is uncertain.
Propylthiouracil
Propylthiouracil is often preferred during the first trimester when antithyroid medication is needed.
However, it carries a risk of serious liver injury.
Later pregnancy
Excessive antithyroid therapy can cause fetal hypothyroidism or goiter.
Maternal disease
Uncontrolled hyperthyroidism can also cause miscarriage, preterm birth, maternal cardiac complications, and other serious problems.
Iodine
Adequate iodine is essential for normal fetal thyroid and brain development.
Both iodine deficiency and excessive iodine exposure can harm fetal thyroid function.
Clinical principle
Thyroid disease should be treated appropriately rather than leaving maternal illness uncontrolled because of concern about medication exposure.
15. Alcohol
Alcohol is an established developmental toxicant.
Fetal alcohol spectrum disorders
Prenatal alcohol exposure may cause:
- Characteristic facial features in some affected individuals.
- Growth impairment.
- Learning difficulties.
- Impaired executive functioning.
- Attention and behavioral disorders.
- Intellectual disability.
- Other neurodevelopmental abnormalities.
Timing
Alcohol can affect the fetal brain throughout pregnancy.
Risk
Risk depends on exposure pattern and individual susceptibility.
Heavy and repeated exposure is particularly concerning.
Current recommendation
There is no known safe amount of alcohol during pregnancy and no established safe time to drink.
Abstinence is recommended.
Important clarification
An isolated exposure does not establish that fetal alcohol spectrum disorder will occur.
Patients should receive individualized counseling rather than assuming the worst outcome.
16. Tobacco, nicotine, and cannabis
Tobacco
Maternal smoking increases the risk of:
- Fetal growth restriction.
- Low birth weight.
- Placental abruption.
- Preterm birth.
- Stillbirth.
- Sudden infant death syndrome.
Nicotine products
Nicotine itself can affect fetal development.
Vaping and other nicotine-delivery products should not be